Cancer Lett 2011 Dec;312 (1): 109-16. [IF:4.864]
Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft.
Fu XH , Li J , Zou Y , Hong YR , Fu ZX , Huang JJ , Zhang SZ , Zheng S .
Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.
浙江大学恶性肿瘤预警与干预教育部重点实验室，浙江大学第二附属医院
Abstract
Vascular-targeting agents (VTAs) can be divided into two groups: anti-angiogenesis agents and vascular disrupting agents (VDAs). The purpose of this study was to evaluate the antineoplastic activity of a combination of the anti-angiogenesis agent, Endostar, and the VDA combretastatin, A4 phosphate (CA4P). This study is the first to evaluate the activity of this combination against tumors and the first to investigate the activity of the combination against osteosarcoma. Endostar combined with CA4P had a good anti-tumor effect with no significant toxicity, and was at least not inferior to adriamycin, which is the main drug for osteosarcoma. The use of VDAs combined with anti-angiogenic drugs can result in significantly enhanced anti-tumor effects, providing a novel approach to cancer treatment, which could effectively complement standard treatments. It is believed that this exciting new treatment has the potential to transform the management of cancer.
摘要：
血管靶向因子(VTAs)可以被分为两类：血管生成抑制因子和血管破坏因子。本研究的目的是评估血管生成抑制因子（恩度）和血管破坏因子（考布他汀A4磷酸盐CA4P）的联合抗肿瘤效应。研究首先评估了这种联合制剂抗肿瘤的效应，并证实这种联合制剂可以对抗骨肉瘤。恩度联合CA4P具有明显的抗肿瘤特性，但是无显著毒性，至少优于治疗骨肉瘤主要的抗肿瘤药物阿霉素。血管生成抑制因子和血管破坏因子药物的联合应用可以显著提高抗肿瘤的效果，为肿瘤治疗提供新的思路，以补充肿瘤目前的标准治疗。这个振奋人心的新的治疗方法可能会改变肿瘤目前的治疗方案。
